• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Med . Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age

tetano

Editor, Senior Moderator
J Clin Med


. 2021 Oct 8;10(19):4606.
doi: 10.3390/jcm10194606.
Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age


Margarethe Konik[SUP] 1 [/SUP], Monika Lindemann[SUP] 2 [/SUP], Markus Zettler[SUP] 1 [/SUP], Lara Meller[SUP] 1 [/SUP], Sebastian Dolff[SUP] 1 [/SUP], Vera Rebmann[SUP] 2 [/SUP], Peter A Horn[SUP] 2 [/SUP], Ulf Dittmer[SUP] 3 [/SUP], Adalbert Krawczyk[SUP] 1 [/SUP], Leonie Schipper[SUP] 1 [/SUP], Mirko Trilling[SUP] 3 [/SUP], Olympia Evdoxia Anastasiou[SUP] 3 [/SUP], Sina Schwarzkopf[SUP] 2 [/SUP], Laura Thümmler[SUP] 2 [/SUP], Christian Taube[SUP] 4 [/SUP], Christoph Schöbel[SUP] 4 [/SUP], Thorsten Brenner[SUP] 5 [/SUP], Eva-Maria Skoda[SUP] 6 [/SUP], Benjamin Wilde[SUP] 7 [/SUP], Anja Gäckler[SUP] 7 [/SUP], Oliver Witzke[SUP] 1 [/SUP], Hana Rohn[SUP] 1 [/SUP]



Affiliations

Abstract

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently the greatest medical challenge. Although crucial to the future management of the pandemic, the factors affecting the persistence of long-term SARS-CoV-2 immunity are not well understood. Therefore, we determined the extent of important correlates of SARS-CoV-2 specific protection in 200 unvaccinated convalescents after COVID-19. To investigate the effective memory response against the virus, SARS-CoV-2 specific T cell and humoral immunity (including virus-neutralizing antibodies) was determined over a period of one to eleven months. SARS-CoV-2 specific immune responses were present in 90% of individual patients. Notably, immunosuppressed patients did not have long-term SARS-CoV-2 specific T cell immunity. In our cohort, the severity of the initial illness influenced SARS-CoV-2 specific T cell immune responses and patients' humoral immune responses to Spike (S) protein over the long-term, whereas the patients' age influenced Membrane (M) protein-specific T cell responses. Thus, our study not only demonstrated the long-term persistence of SARS-CoV-2 specific immunity, it also determined COVID-19 severity and patient age as significant factors affecting long-term immunity.

Keywords: COVID-19; Membrane protein; SARS-CoV-2; SARS-CoV-2 IgG; T cell; age; immunity; spike protein.
 
Back
Top Bottom